Castle Biosciences (CSTL) announced that on Dec. 15, the Compensation Committee of its Board of Directors granted restricted stock units to 83 employees covering an aggregate of 139,494 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company’s 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to the employee’s continued service through each applicable vesting date.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences announces new data on DecisionDx-UM, PRAME
- Castle Biosciences price target raised to $50 from $38 at BTIG
- Castle Biosciences announces publication of new SRMA on TissueCypher
- Castle announces publication of consensus paper on DecisionDx-Melanoma test
- Castle Biosciences announces new data on DecisionDx-Melanoma test
